Phase 2
Completed N=223
ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension
Source: ClinicalTrials.gov NCT03295734 ↗Enrolled (actual)
223
Serious AEs
3.6%
Results posted
Jul 2025
Primary outcomePrimary: Change in Gait Speed From Baseline — 0.10; 0.05; 0.10 m/sec
Summary
The purpose of this project is to conduct a randomized, controlled trial (RCT) to determine if choice of antihypertensive medication influences changes in functional status and other cardiovascular risk factors among older persons with hypertension when combined with physical exercise.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Gait Speed From Baseline |
0.10; 0.05; 0.10 | — |
Eligibility Criteria
Inclusion Criteria
- Age 60 years and older
- Hypertension - untreated (SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg) or treated
- > 290 seconds needed to complete long-distance corridor walk test
- Sedentary lifestyle, defined as 140/90, despite the use of three or more anti-hypertensive drugs
- SBP > 180 mm Hg or DBP > 110 mm Hg
- Chronic kidney disease
- Serum creatinine >2.5 mg/dL in men or >2.0 mg/dL in women
- Serum potassium outside normal reference range
- Urinary protein > 1 on dipstick
- Abnormal liver enzymes (AST, ALT, or alkaline phosphatase > 2.5 times the upper limit of normal)
- Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina
- Acute myocardial infarction identified by ECG
- Significant cognitive impairment, defined as a known diagnosis of dementia or a Mini-Mental State Examination exam score < 24;
- Simultaneous participation in another intervention trial
- Known hypersensitivity to ACE inhibitors (exclusion only to perindopril arm; will be randomized among other two interventions)
- Any other condition that would preclude participating based upon judgement of PI or study clinician team
Data sourced from ClinicalTrials.gov (NCT03295734). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.